Cargando…
Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand
The severe acute respiratory syndrome 2 (SARS-CoV-2) has spread rapidly worldwide, not only causing significant morbidity and mortality but also dramatically increasing health care spending. To manage this in Thailand, healthcare workers first received two doses of the CoronaVac vaccine followed by...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940472/ https://www.ncbi.nlm.nih.gov/pubmed/36845212 http://dx.doi.org/10.1016/j.jvacx.2023.100277 |
_version_ | 1784891085007355904 |
---|---|
author | Phumisantiphong, Uraporn Chunhakan, Sirichan Manomaipiboon, Anan Maneerit, Jakravoot Dechanuwong, Pornchai Trakarnvanich, Thananda Oajaum, Wadakorn Chan-in, Wilawan |
author_facet | Phumisantiphong, Uraporn Chunhakan, Sirichan Manomaipiboon, Anan Maneerit, Jakravoot Dechanuwong, Pornchai Trakarnvanich, Thananda Oajaum, Wadakorn Chan-in, Wilawan |
author_sort | Phumisantiphong, Uraporn |
collection | PubMed |
description | The severe acute respiratory syndrome 2 (SARS-CoV-2) has spread rapidly worldwide, not only causing significant morbidity and mortality but also dramatically increasing health care spending. To manage this in Thailand, healthcare workers first received two doses of the CoronaVac vaccine followed by a booster vaccine with either BNT162b2 vaccine (Pfizer-BioNTech; PZ) or ChAdOx1 nCoV-19 vaccine (Oxford–AstraZeneca; AZ). Given that the difference in anti-SARS-CoV-2 levels following vaccination may vary depending on the vaccine and on demographic characteristics, we measured the antibody response after the second CoronaVac dose and after the booster with either the PZ or AZ vaccine. Our results in 473 healthcare workers show that the variation in antibody response to the full CoronaVac dose depends on demographic characteristics such as age, gender, body mass index, and underlying disease. After receiving a booster dose, anti-SARS-CoV-2 levels were significantly higher in participants who received the PZ vaccine than in people who received the AZ vaccine. Overall, however, receiving a booster dose of either the PZ or AZ vaccine promoted strong antibody responses, even in the old and those with obesity or diabetes mellitus. In conclusion, our results support the use of a booster vaccination program after full vaccination with the CoronaVac vaccine. This approach effectively enhances immunity against SARS-CoV-2, especially in clinically vulnerable groups and healthcare workers. |
format | Online Article Text |
id | pubmed-9940472 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-99404722023-02-21 Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand Phumisantiphong, Uraporn Chunhakan, Sirichan Manomaipiboon, Anan Maneerit, Jakravoot Dechanuwong, Pornchai Trakarnvanich, Thananda Oajaum, Wadakorn Chan-in, Wilawan Vaccine X Regular paper The severe acute respiratory syndrome 2 (SARS-CoV-2) has spread rapidly worldwide, not only causing significant morbidity and mortality but also dramatically increasing health care spending. To manage this in Thailand, healthcare workers first received two doses of the CoronaVac vaccine followed by a booster vaccine with either BNT162b2 vaccine (Pfizer-BioNTech; PZ) or ChAdOx1 nCoV-19 vaccine (Oxford–AstraZeneca; AZ). Given that the difference in anti-SARS-CoV-2 levels following vaccination may vary depending on the vaccine and on demographic characteristics, we measured the antibody response after the second CoronaVac dose and after the booster with either the PZ or AZ vaccine. Our results in 473 healthcare workers show that the variation in antibody response to the full CoronaVac dose depends on demographic characteristics such as age, gender, body mass index, and underlying disease. After receiving a booster dose, anti-SARS-CoV-2 levels were significantly higher in participants who received the PZ vaccine than in people who received the AZ vaccine. Overall, however, receiving a booster dose of either the PZ or AZ vaccine promoted strong antibody responses, even in the old and those with obesity or diabetes mellitus. In conclusion, our results support the use of a booster vaccination program after full vaccination with the CoronaVac vaccine. This approach effectively enhances immunity against SARS-CoV-2, especially in clinically vulnerable groups and healthcare workers. Elsevier 2023-02-20 /pmc/articles/PMC9940472/ /pubmed/36845212 http://dx.doi.org/10.1016/j.jvacx.2023.100277 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Regular paper Phumisantiphong, Uraporn Chunhakan, Sirichan Manomaipiboon, Anan Maneerit, Jakravoot Dechanuwong, Pornchai Trakarnvanich, Thananda Oajaum, Wadakorn Chan-in, Wilawan Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand |
title | Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand |
title_full | Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand |
title_fullStr | Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand |
title_full_unstemmed | Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand |
title_short | Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand |
title_sort | comparison of antibody responses before and after booster doses with the pfizer-biontech or oxford–astrazeneca vaccines in healthcare workers in thailand |
topic | Regular paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940472/ https://www.ncbi.nlm.nih.gov/pubmed/36845212 http://dx.doi.org/10.1016/j.jvacx.2023.100277 |
work_keys_str_mv | AT phumisantiphonguraporn comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand AT chunhakansirichan comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand AT manomaipiboonanan comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand AT maneeritjakravoot comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand AT dechanuwongpornchai comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand AT trakarnvanichthananda comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand AT oajaumwadakorn comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand AT chaninwilawan comparisonofantibodyresponsesbeforeandafterboosterdoseswiththepfizerbiontechoroxfordastrazenecavaccinesinhealthcareworkersinthailand |